AOD-9604: How to Safely Stop Treatment

How AOD-9604 Works and Why Stopping Is Straightforward

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone, with the addition of a tyrosine residue at the N-terminus. Unlike full-length GH, this fragment stimulates lipolysis and inhibits lipogenesis without binding the growth hormone receptor in a way that triggers downstream IGF-1 production 1. This distinction is the pharmacological reason stopping AOD-9604 is simpler than discontinuing exogenous growth hormone itself.

Full-length recombinant GH (somatropin) suppresses endogenous GH secretion through negative feedback on the hypothalamic-pituitary axis, mediated by elevated IGF-1 levels 2. AOD-9604 does not produce this suppression. Heffernan et al. demonstrated in 2001 that the fragment retained the lipolytic activity of the full GH molecule in obese Zucker rats while showing no effect on longitudinal bone growth or IGF-1 levels 1. A follow-up study confirmed that the lipolytic mechanism operates through a pathway distinct from the canonical GH receptor signaling cascade, instead involving beta-3 adrenergic receptor-adjacent pathways in adipose tissue 3.

Because the compound does not alter the GH-IGF-1 axis, there is no physiological deficit to "recover from" upon cessation. This separates AOD-9604 from agents that require careful discontinuation planning, such as corticosteroids (which suppress the hypothalamic-pituitary-adrenal axis) 4 or exogenous testosterone (which suppresses gonadal function) 5.

When to Stop: Defining the End of a Treatment Cycle

Most prescribing clinicians structure AOD-9604 therapy as fixed-length cycles. The compound is not FDA-approved for any indication, and prescribing occurs exclusively through 503A compounding pharmacies under clinical oversight 6. A typical protocol runs 8 to 12 weeks at doses of 250 to 500 mcg administered subcutaneously once daily, usually before breakfast or before sleep.

Three clinical signals guide the decision to stop:

Goal attainment. If the patient has reached a target reduction in adipose tissue (commonly assessed by waist circumference, DEXA body composition, or serial skinfold measurements), the cycle ends. The Endocrine Society recommends DEXA as the reference standard for body composition assessment in clinical research settings 7.

Plateau in response. Fat-loss velocity that drops to near zero over two consecutive weeks suggests receptor desensitization or maximal response at the current dose. Continuing beyond this point adds cost without benefit.

Adverse effects. While AOD-9604 has a mild side-effect profile in published data, injection-site erythema, transient headache, or gastrointestinal discomfort may prompt early discontinuation. Stegall et al. noted that the peptide fragment was well tolerated in Phase IIb trials, though detailed adverse-event breakdowns remain limited in the public literature 8.

The Discontinuation Protocol: Step by Step

Because AOD-9604 does not create physiological dependence, the discontinuation process is administrative rather than pharmacological. Still, a structured approach prevents unnecessary anxiety and ensures metabolic stability.

Week 1 of cessation: Stop injections. Abrupt discontinuation is appropriate. The peptide's half-life is short (estimated at 30 to 45 minutes based on its molecular weight and subcutaneous absorption kinetics), meaning plasma levels fall to negligible within hours of the final dose 9. No tapering schedule is supported by published evidence.

Days 3 to 7: Monitor subjective symptoms. Patients should track appetite, energy, and sleep quality in a simple log. AOD-9604 does not cross the blood-brain barrier in meaningful concentrations 3, so central nervous system withdrawal symptoms are not expected. Any appetite increase likely reflects a return to baseline hunger signaling rather than a rebound phenomenon.

Week 2: Baseline bloodwork. A post-cessation lab panel should include fasting glucose, HbA1c (if the patient has prediabetes or metabolic syndrome), a standard lipid panel, and IGF-1. The American Association of Clinical Endocrinology (AACE) recommends metabolic panels for any patient on peptide therapies that target adipose tissue 10. IGF-1 should remain within the age-adjusted reference range, confirming no occult GH-axis disruption.

Weeks 2 to 4: Reinforce nutritional and exercise habits. The most common "rebound" patients report is not pharmacological. It is behavioral. A 2021 systematic review of anti-obesity medication discontinuation found that weight regain after drug cessation is primarily driven by the return of pre-treatment caloric intake patterns and loss of medication-induced appetite modulation 11. For AOD-9604, where the mechanism is lipolytic rather than anorexigenic, the risk is somewhat lower, but caloric vigilance remains relevant.

Week 4 to 8: Follow-up body composition measurement. A DEXA scan or equivalent assessment 4 to 8 weeks after the last injection establishes whether fat-loss results are durable. Published peptide data suggest that lean mass maintained through resistance training persists better than fat loss maintained through caloric restriction alone 12.

What Not to Expect: Withdrawal, Rebound, and Hormonal Disruption

No withdrawal syndrome has been reported for AOD-9604 in any published study. This is consistent with its mechanism: the peptide does not modulate neurotransmitter systems, opioid receptors, or the hypothalamic-pituitary axis 1.

No IGF-1 suppression. Full-length GH therapy at pharmacologic doses (0.4 to 0.8 mg/day) raises IGF-1 to supraphysiologic levels, and abrupt cessation can leave patients in a transient IGF-1 trough. AOD-9604 does not raise IGF-1 in the first place. Heffernan's 2001 data showed no change in circulating IGF-1 levels in treated animals compared to controls 1. Human Phase II data, while limited, corroborated this finding 8.

No adrenal suppression. The compound does not interact with cortisol synthesis or ACTH secretion. Patients do not need the graduated dose reduction required when stopping glucocorticoids after prolonged use 4.

No rebound lipogenesis. Some GH-axis compounds create a transient lipogenic state upon withdrawal due to the mismatch between suddenly low GH-driven lipolysis and ongoing insulin-mediated lipogenesis 13. Because AOD-9604 operates outside the GH receptor pathway, this mismatch does not occur. Fat regain, if it happens, reflects caloric surplus rather than a pharmacological rebound.

No mood disruption. Unlike GH-releasing peptides such as tesamorelin that influence ghrelin-related pathways and can affect mood and appetite centrally 14, AOD-9604 acts peripherally on adipocytes. Patients should not expect mood changes, sleep disturbance, or cognitive fog upon stopping.

Special Populations: Adjusting the Approach

Patients with metabolic syndrome. Those using AOD-9604 alongside metformin or GLP-1 receptor agonists should coordinate discontinuation with their prescriber. Removing one adipose-modulating agent while continuing another may alter the risk-benefit calculus. The ADA Standards of Care emphasize individualized de-escalation when adjusting anti-obesity pharmacotherapy 15.

Patients stacking multiple peptides. Some protocols combine AOD-9604 with CJC-1295 or ipamorelin (GH-releasing peptides). These co-administered peptides DO affect the GH-IGF-1 axis and require their own discontinuation considerations 16. Stopping AOD-9604 alone does not address the axis suppression risk posed by GH secretagogues. Each compound should be evaluated independently.

Post-bariatric surgery patients. Peptide use in the post-bariatric population is increasing, though evidence is thin. Altered gastrointestinal physiology after Roux-en-Y or sleeve gastrectomy may affect subcutaneous drug absorption kinetics 17. Discontinuation timing should account for the accelerated metabolic changes already occurring from the surgical intervention.

Monitoring After Discontinuation

A structured monitoring plan confirms that cessation has not introduced metabolic instability.

| Timepoint | Test | Purpose | |---|---|---| | Week 2 post-stop | Fasting glucose, lipid panel, IGF-1 | Confirm no metabolic disruption | | Week 4 post-stop | Body weight, waist circumference | Track early trajectory | | Week 8 post-stop | DEXA or equivalent | Assess fat-mass durability | | Week 12 post-stop | Repeat metabolic panel if abnormalities at Week 2 | Ensure resolution |

The Endocrine Society's 2015 guidelines on GH use in adults recommend IGF-1 monitoring whenever GH-related peptides are started or stopped, as a safety measure even when axis suppression is not expected 18.

Re-Starting AOD-9604: Cycling Considerations

Most clinicians recommend a washout period of 4 to 8 weeks between cycles. This interval is empirical rather than evidence-based, derived from general peptide-cycling principles rather than AOD-9604-specific pharmacokinetic data. The rationale includes allowing receptor sensitivity to normalize, reassessing body composition without pharmacologic assistance, and confirming that lifestyle habits can independently maintain progress.

If the first cycle produced measurable results (typically 2 to 4 kg of fat loss over 12 weeks based on available trial data 8), a second cycle at the same dose is reasonable. Dose escalation beyond 500 mcg/day lacks published safety data.

Patients who saw no response after a full 12-week cycle at 500 mcg/day are unlikely to benefit from additional cycles. A candid reassessment of diagnosis, adherence, and alternative therapies (including FDA-approved options such as semaglutide or tirzepatide 19) is more productive than repeated empiric trials of a non-approved peptide.

The Regulatory Context for Discontinuation Decisions

AOD-9604 occupies a legally ambiguous space in the U.S. The FDA's 2024 updated guidance on bulk drug substances under Section 503A lists specific conditions under which compounding pharmacies may prepare peptide formulations 6. AOD-9604 is not FDA-approved, has no completed Phase III program, and carries no official prescribing information or discontinuation label guidance.

This regulatory gap means discontinuation protocols are clinician-driven, based on first principles of peptide pharmacology and extrapolation from related compounds. Patients should work with a provider experienced in peptide therapy rather than self-managing cessation based on online forums or anecdotal reports.

The median post-cessation follow-up visit should include a documented assessment confirming stable fasting glucose (target <100 mg/dL), IGF-1 within reference range, and stable or improved body composition relative to pre-treatment baseline.